Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1976 3
1977 4
1978 2
1979 2
1981 4
1982 2
1983 3
1984 5
1985 7
1986 4
1987 9
1988 9
1989 12
1990 12
1991 14
1992 14
1993 20
1994 13
1995 14
1996 20
1997 15
1998 21
1999 23
2000 21
2001 19
2002 29
2003 28
2004 28
2005 32
2006 21
2007 23
2008 38
2009 30
2010 41
2011 34
2012 41
2013 47
2014 35
2015 41
2016 44
2017 44
2018 33
2019 33
2020 45
2021 44
2022 41
2023 36
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

978 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Anemia due to Decreased Production"
Page 1
How do we treat life-threatening anemia in a Jehovah's Witness patient?
Posluszny JA Jr, Napolitano LM. Posluszny JA Jr, et al. Transfusion. 2014 Dec;54(12):3026-34. doi: 10.1111/trf.12888. Epub 2014 Oct 21. Transfusion. 2014. PMID: 25330835 Free article.
The refusal of allogeneic human blood and blood products by Jehovah's Witness (JW) patients complicates the treatment of life-threatening anemia. ...We describe a protocol-based algorithm to the management of life-threatening anemia in JW patients and review …
The refusal of allogeneic human blood and blood products by Jehovah's Witness (JW) patients complicates the treatment of life-threate …
How I treat cancer-associated anemia.
Gilreath JA, Rodgers GM. Gilreath JA, et al. Blood. 2020 Aug 13;136(7):801-813. doi: 10.1182/blood.2019004017. Blood. 2020. PMID: 32556170 Free article. Review.
Despite increasing use of targeted therapies to treat cancer, anemia remains a common complication of cancer therapy. Physician concerns about the safety of intravenous (IV) iron products and erythropoiesis-stimulating agents (ESAs) have resulted in many patients wi …
Despite increasing use of targeted therapies to treat cancer, anemia remains a common complication of cancer therapy. Physician conce …
Nutrition-specific interventions for preventing and controlling anaemia throughout the life cycle: an overview of systematic reviews.
da Silva Lopes K, Yamaji N, Rahman MO, Suto M, Takemoto Y, Garcia-Casal MN, Ota E. da Silva Lopes K, et al. Cochrane Database Syst Rev. 2021 Sep 26;9(9):CD013092. doi: 10.1002/14651858.CD013092.pub2. Cochrane Database Syst Rev. 2021. PMID: 34564844 Free PMC article. Review.
We followed standard Cochrane methodology, extracting GRADE ratings where provided. The primary outcomes were haemoglobin (Hb) concentration, anaemia, and iron deficiency anaemia (IDA); secondary outcomes were iron deficiency (ID), severe anaemia and adverse …
We followed standard Cochrane methodology, extracting GRADE ratings where provided. The primary outcomes were haemoglobin (Hb) concentration …
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, Reinisch W, Iqbal T. Zoller H, et al. Gut. 2023 Apr;72(4):644-653. doi: 10.1136/gutjnl-2022-327897. Epub 2022 Sep 9. Gut. 2023. PMID: 36343979 Free PMC article. Clinical Trial.
DESIGN: This randomised, double-blind, clinical trial was conducted at 20 outpatient hospital clinics in Europe (Austria, Denmark, Germany, Sweden, UK). Adults with IBD and iron deficiency anaemia (IDA) were randomised 1:1 to receive FCM or FDI …
DESIGN: This randomised, double-blind, clinical trial was conducted at 20 outpatient hospital clinics in Europe (Austri …
Neonatal anemia.
Aher S, Malwatkar K, Kadam S. Aher S, et al. Semin Fetal Neonatal Med. 2008 Aug;13(4):239-47. doi: 10.1016/j.siny.2008.02.009. Epub 2008 Apr 14. Semin Fetal Neonatal Med. 2008. PMID: 18411074 Review.
Neonatal anemia can be due to blood loss, decreased RBC production, or increased destruction of erythrocytes. Physiologic anemia of the newborn and anemia of prematurity are the two most common causes of anemia in neonates. ...
Neonatal anemia can be due to blood loss, decreased RBC production, or increased destruction of erythrocytes. Physiolog …
Anemia and transfusion in the neonate.
Colombatti R, Sainati L, Trevisanuto D. Colombatti R, et al. Semin Fetal Neonatal Med. 2016 Feb;21(1):2-9. doi: 10.1016/j.siny.2015.12.001. Epub 2015 Dec 28. Semin Fetal Neonatal Med. 2016. PMID: 26732078 Review.
Neonatal anemia is a frequent occurrence in neonatal intensive care units. Red blood cell transfusion criteria in case of blood loss are clearly defined but optimal hemoglobin or hematocrit thresholds of transfusion for anemia due to decreased production …
Neonatal anemia is a frequent occurrence in neonatal intensive care units. Red blood cell transfusion criteria in case of blood loss …
Erythropoietin in obstetrics.
Vora M, Gruslin A. Vora M, et al. Obstet Gynecol Surv. 1998 Aug;53(8):500-8. doi: 10.1097/00006254-199808000-00023. Obstet Gynecol Surv. 1998. PMID: 9702790 Review.
In addition, erythropoietin levels have been well correlated with perinatal brain damage and may facilitate treatment of high risk neonates. Erythropoietin has also been used successfully in anemia of prematurity, decreasing the transfusion requirement. However, stu …
In addition, erythropoietin levels have been well correlated with perinatal brain damage and may facilitate treatment of high risk neonates. …
Mitapivat for sickle cell disease and thalassemia.
Pilo F, Angelucci E. Pilo F, et al. Drugs Today (Barc). 2023 Mar;59(3):125-134. doi: 10.1358/dot.2023.59.3.3521880. Drugs Today (Barc). 2023. PMID: 36847623 Clinical Trial.
It was approved in 2022 for the treatment of PKD and is being explored in other hereditary chronic conditions that are associated with hemolytic mechanisms of anemia, such as sickle cell disease (SCD) and thalassemia. In a proof-of-concept phase I study in SCD, treatment w …
It was approved in 2022 for the treatment of PKD and is being explored in other hereditary chronic conditions that are associated with hemol …
Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
Locatelli F, Minutolo R, De Nicola L, Del Vecchio L. Locatelli F, et al. Drugs. 2022 Nov;82(16):1565-1589. doi: 10.1007/s40265-022-01783-3. Epub 2022 Nov 9. Drugs. 2022. PMID: 36350500 Free PMC article. Review.
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population; anaemia is a frequent complication. Inadequate erythropoietin production and absolute or functional iron deficiency are the major causes. ...Some molecules are already approved for …
Chronic kidney disease (CKD) affects approximately 10% of the worldwide population; anaemia is a frequent complication. Inadequate er …
Iron Metabolism in Chronic Kidney Disease Patients.
Honda H, Hosaka N, Ganz T, Shibata T. Honda H, et al. Contrib Nephrol. 2019;198:103-111. doi: 10.1159/000496369. Epub 2019 Apr 16. Contrib Nephrol. 2019. PMID: 30991401 Review.
BACKGROUND: Anemia is a common comorbidity in patients with chronic kidney disease (CKD) and occurs due to diminished renal function. The main cause of such anemia is decreased erythropoietin (EPO) production and secretion from the kidney and a lower e …
BACKGROUND: Anemia is a common comorbidity in patients with chronic kidney disease (CKD) and occurs due to diminished renal function. …
978 results